S. Flechter

发表

Towards personalized therapy for multiple sclerosis: prediction of individual treatment response

Pierre Grammond, Patrizia Sola, Murat Terzi, 2017, Brain : a journal of neurology.

Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis

Pierre Grammond, Patrizia Sola, Guillermo Izquierdo, 2016, Journal of Neurology, Neurosurgery & Psychiatry.

Sex as a determinant of relapse incidence and progressive course of multiple sclerosis.

J. Lechner-Scott, M. Slee, M. Trojano, 2013, Brain : a journal of neurology.

Immunoglobulin free light chains in saliva: a potential marker for disease activity in multiple sclerosis

I. Ben-Zvi, S. Flechter, A. Livneh, 2018, Clinical and experimental immunology.

Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod

A. Achiron, G. Harari, D. Magalashvili, 2022, Journal of Neurology.

SARS‐CoV‐2 memory B and T cell profiles in mild COVID‐19 convalescent patients

A. Achiron, D. Magalashvili, M. Gurevich, 2021, International Journal of Infectious Diseases.

The central nervous sytem-specific myelin oligodendrocytic basic protein (MOBP) is encephalitogenic and a potential target antigen in multiple sclerosis (MS)

A. Ben-nun, S. Flechter, M. Hoffman, 2000, Journal of Neuroimmunology.

COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021

A. Achiron, S. Miron, U. Givon, 2021, Multiple sclerosis.

Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies

A. Achiron, G. Harari, D. Magalashvili, 2021, Therapeutic advances in neurological disorders.

Copolymer 1 (Glatiramer Acetate) in Relapsing Forms of Multiple Sclerosis: Open Multicenter Study of Alternate-Day Administration

A. Korczyn, S. Flechter, B. Steiner-Birmanns, 2002, Clinical neuropharmacology.

Glatiramer Acetate Depot (extended-release) Phase IIa one-year study in patients with Relapsing-remitting Multiple Sclerosis: Safety, tolerability and efficacy – NEDA Analysis (P6.359)

J. Chapman, Ariel Miller, D. Karussis, 2018 .

Septal dopaminergic–cholinergic interactions during stress

Y. Finkelstein, I. Hod, S. Flechter, 1990 .

Approach to bilateral benign paroxysmal positioning vertigo.

L. Pollak, S. Flechter, R. Stryjer, 2006, American journal of otolaryngology.

Influence of histocompatibility genes on disease susceptibility and treatment response in patients with relapsing-remitting multiple sclerosis treated with interferon β-1a

L. Pollak, S. Flechter, T. Klein, 2011, Neurology international.

The effect of additional ankle and midfoot mobilizations on plantar fasciitis: a randomized controlled trial.

Leonid Kalichman, S. Flechter, Anat Shashua, 2015, The Journal of orthopaedic and sports physical therapy.

Seasonal variation of relapse rate in multiple sclerosis is latitude dependent

J. Lechner-Scott, M. Slee, M. Trojano, 2014, Annals of neurology.

Predominance of the autoimmune response to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis: Reactivity to the extracellular domain of MOG is directed against three main regions

A. Ben-nun, O. Abramsky, S. Flechter, 1997, European journal of immunology.

In vitro presynaptic modulation of cholinergic hippocampal activity by pituitary-adrenocortical hormones

I. Hod, S. Flechter, Y. Finkelstein, 1987, Experimental Neurology.

COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose

A. Achiron, S. Miron, U. Givon, 2022, Journal of the Neurological Sciences.

Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study

A. Achiron, U. Givon, G. Harari, 2021, Journal of Neuroimmunology.

Delay from treatment start to full effect of immunotherapies for multiple sclerosis.

L. Kappos, P. Vermersch, E. Leray, 2020, Brain : a journal of neurology.

Author response to: Correspondence to humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies

A. Achiron, G. Harari, D. Magalashvili, 2021, Therapeutic advances in neurological disorders.

Cognitive dysfunction evaluation in multiple sclerosis patients treated with interferon beta-1b: an open-label prospective 1 year study.

L. Pollak, J. Vardi, S. Flechter, 2007, The Israel Medical Association journal : IMAJ.

Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS

Alexander Parajeles Vindas, P. Kowey, D. Arnold, 2016, Neurology. Clinical practice.

Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing–remitting multiple sclerosis

J. Lechner-Scott, M. Slee, M. Trojano, 2015, Multiple sclerosis.

Cladribine treatment for highly active multiple sclerosis: Real-world clinical outcomes for years 3 and 4

A. Achiron, G. Harari, D. Magalashvili, 2022, Journal of Neuroimmunology.

Phobic postural vertigo: a new proposed entity.

L. Pollak, C. Klein, S. Flechter, 2003, The Israel Medical Association journal : IMAJ.

Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies

A. Achiron, G. Harari, D. Magalashvili, 2021, Therapeutic Advances in Neurological Disorders.

COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021

A. Achiron, S. Miron, U. Givon, 2021, Multiple Sclerosis Journal.

Electroencephalographic Abnormalities in Aseptic Meningitis and Noninfectious Headache. A Comparative Study

L. Pollak, J. Rabey, C. Klein, 2001, Headache.